在帕金森病中,GBA1与 lysosomal 功能障碍和炎症的相互作用
Ruochen Wang1, Taku Hatano1, Nobutaka Hattori1
1Department of Neurology, Juntendo University, Tokyo, Japan.
Neural regeneration research
|December 30, 2025
概括
帕金森病的风险是显著增加在葡萄糖大脑酶 (GBA1) 基因的突变. 这些GBA1变异导致神经炎症和α-synuclein聚合,推动疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 葡萄糖脑糖酶 (GBA1) 基因的突变是帕金森病 (PD) 的主要遗传风险因素.
- GBA1变异与一个独特的PD亚型有关,具有早期发病和认知障碍.
- 这些突变破坏了 lysosomal 功能,导致α-synuclein 聚合和神经炎症.
研究的目的:
- 审查将GBA1功能障碍与PD病变发生联系起来的分子机制.
- 探索GBA1突变在 lysosomal-autophagy通路和神经炎症中的作用.
- 评估GBA1相关PD的新兴治疗策略.
主要方法:
- 文献综述综合了关于GBA1突变和PD的当前研究.
- 分析分子途径,包括脂代谢,ER压力和蛋白质聚合.
- 检查细胞交叉声 (溶酶体-线粒体-自) 和神经炎症级联.
主要成果:
- GBA1突变导致脂质的有毒积累,并影响蛋白质清除.
- 存在一个反循环,GBA1缺乏促进了α-synuclein聚合,这进一步阻碍了GBA1的功能.
- 损伤的自和 lysosomal 功能障碍放大氧化应激和激活炎症体,涉及多种质细胞类型.
结论:
- GBA1突变启动了一系列复杂的分子和细胞功能障碍,导致PD.
- 新兴疗法显示出希望,但面临诸如血脑屏障透等挑战.
- 针对特定GBA1突变的精准医学方法对于有效治疗至关重要.
关键词:
帕金森病是帕金森病的一种.自-溶酶体通路自 - 溶酶体通路溶酶体功能障碍 溶酶体功能障碍微生物组-肠道-大脑轴线粒体中的线粒体.神经退行症的神经退行症神经炎症是一种神经炎症.精准医学是一门精准医学.α-synuclein 是一种同核蛋白.更多相关视频
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.5K
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
2.1K
相关概念视频
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
